Professor of Medicine
University of Washington
Anna Wald, MD, MPH, FIDSA, is the Head of Allergy and Infectious Diseases Division, Professor of Medicine, Epidemiology, and Laboratory Medicine & Pathology at the University of Washington and at the Vaccine and Infectious Division, Fred Hutchinson Cancer Research Center. Dr. Wald directs the University of Washington Virology Research Clinic, a clinic dedicated to the study of epidemiology, natural history, and therapeutics for viral infections. Her research has focused on genital herpes infections, including infections in pregnant women and immunocompromised hosts. She has been an investigator in many clinical trials for novel antiviral agents, and prophylactic and therapeutic vaccines for HSV infection, as well as vaccines for HPV, CMV and other viral pathogens.
Dr. Wald has been supported by NIH throughout her career. In addition to grants for scientific investigations, she has received a K24 Mentor Award from NIAID which supported the mentoring of the next generation of physician scientists. Clinically, Dr. Wald cares for patients with infections at an urban hospital in Seattle, and for patients with infectious complications of hematopoietic transplant and malignancies. She is a member of the Association of American Physicians, has received the ASTDA Distinguished Career Award, and has been selected as a Woman of ID by the IDSA Foundation.
Dr. Wald received her BA from the Wesleyan University in Middletown, CT and MD from Mount Sinai School of Medicine in New York City. She trained in Internal Medicine at Boston City Hospital and completed a fellowship in Infectious Diseases and MPH from University of Washington in Seattle. Her presentation, “Developing Vaccines for Old and New Pathogens” will discuss the issue of endpoint in the design of vaccine trials and how it impacts the potential for successful development.
Disclosure: Aicuris (Individual(s) Involved: Self): Consultant; Gilead (Individual(s) Involved: Self): Consultant; GlaxoSmithKline (Individual(s) Involved: Self): Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): DSMB participation; provision of vaccine for a study, Other Financial or Material Support; Sanofi (Individual(s) Involved: Self): Scientific Research Study Investigator; X-Vax (Individual(s) Involved: Self): Consultant
Thursday, October 22, 2020
10:30am – 11:00am EDT